panulisib   Click here for help

GtoPdb Ligand ID: 9916

Synonyms: example 96 [WO2012007926A1] | P7170
Compound class: Synthetic organic
Comment: Panulisib (P7170) is a potent small-molecule inhibitor of class I PI3K isoforms, mTOR kinase and activin receptor-like kinase 1 (ALK1) [1,3]. It was developed for antiangiogenic efficacy as a novel cancer therapy and has shown efficacy in in vitro and in vivo models of human non-small cell lung cancer [3]. The chemical structure is claimed in Piramal Life Sciences' patent WO2012007926 where it is example 96 [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 133.97
Molecular weight 527.18
XLogP 4.73
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES N#CN=c1n(c2ccc(nc2)C(C#N)(C)C)c2c(n1C)cnc1c2cc(cc1)c1cnc(c(c1)C(F)(F)F)N
Isomeric SMILES N#CN=c1n(c2ccc(nc2)C(C#N)(C)C)c2c(n1C)cnc1c2cc(cc1)c1cnc(c(c1)C(F)(F)F)N
InChI InChI=1S/C27H20F3N9/c1-26(2,13-31)22-7-5-17(11-35-22)39-23-18-8-15(16-9-19(27(28,29)30)24(33)36-10-16)4-6-20(18)34-12-21(23)38(3)25(39)37-14-32/h4-12H,1-3H3,(H2,33,36)
No information available.
Summary of Clinical Use Click here for help
A Phase 1 clinical study designed to evaluate efficacy of P7170 in advanced refractory solid tumours (NCT01762410) was suspended by the study sponsor (Piramal Enterprises) for reasons unrelated to patient safety.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01762410 Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors Phase 1 Interventional Piramal Enterprises Limited